Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital

Contributed by: Business Wire

Logo

Images

Rubedo Life Sciences scientists. Photo credit: ALESSANDRO GANDOLFI

Business Wire embedded0

Tags

Biotechnology

Other Health

Health

Pharmaceutical

Oncology

Other Science

Research

Infectious Diseases

Genetics

Science

Clinical Trials

Series A Financing

More Like This

Marco Quarta (right), Rubedo Life Sciences CEO and Co-Founder, notarizes the incorporation of Rubedo's European Headquarters in Milan (Photo: Business Wire)

Rubedo Life Sciences Announces European Expansion Ahead of First Clinical Trial

Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board

Rubedo Life Sciences scientists (Photo: Business Wire)

Rubedo Life Sciences and Beiersdorf Announce Multi-Year Partnership to Pioneer New Skin Care Products that Address Cellular Aging

Image created by Clara Leibenguth for Stanford University; featured on cover of May 2025 issue of Nature Neuroscience.

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience

EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing